Invention Publication
- Patent Title: SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
-
Application No.: US18627994Application Date: 2024-04-05
-
Publication No.: US20240269064A1Publication Date: 2024-08-15
- Inventor: Jennifer Eng-Wong , Whitney Kirschbrown , Tarik Ali Khan , Jasper Lin , Sreedhara Alavattam , Amit Garg , Sarah Heeson , Tanja Badovinac-Crnjevic , Christine Wurth
- Applicant: Genentech, Inc. , Hoffmann-La Roche Inc.
- Applicant Address: US CA South San Francisco
- Assignee: Genentech, Inc.,Hoffmann-La Roche Inc.
- Current Assignee: Genentech, Inc.,Hoffmann-La Roche Inc.
- Current Assignee Address: US CA South San Francisco; US NJ Little Falls
- The original application number of the division: US16952670 2020.11.19
- Main IPC: A61K9/00
- IPC: A61K9/00 ; A61K9/08 ; A61K38/47 ; A61K39/00 ; A61K39/395 ; A61K47/18 ; A61K47/20 ; A61K47/26 ; A61P35/00 ; C07K16/28 ; C07K16/30 ; C07K16/32
Abstract:
Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
Information query
